CLOs on the Move


 
Optimizing drug development with innovative instruments & scientific expertise.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Kathy Berardi
General Counsel Profile

Similar Companies

Ionis Pharmaceuticals

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.

Sequella

Sequella is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centaur Pharmaceuticals

Centaur Pharmaceuticals is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cycle Pharmaceuticals

WHAT WE DO Cycle Pharmaceuticals is a global, privately-owned and patient-dedicated biotechnology company headquartered in Cambridge in the UK. Our mission is to utilise the latest pharmaceutical technologies to deliver superior drug treatments to b...

WCG IRB

WCG is the world`s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, the industry`s first central IRB – WCG IRB – and first clinical services organization, WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection.